Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
glaucoma save search
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
Published: 2024-04-10 (Crawled : 20:00) - globenewswire.com
SGHT | $5.57 -1.24% 11K
|
|
| O: 0.17%
H: 6.78%
C: 2.69%
GKOS | $103.29 2.17% 73K
|
Health Technology
|
| O: 0.75%
H: 0.51%
C: -1.19%
omni glaucoma publication sciences system technology study
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Published: 2024-04-06 (Crawled : 16:20) - globenewswire.com
OCUL | News | $4.775 -4.5% 800K
|
Health Technology
| Email alert
Add to watchlist
glaucoma ocular positive meeting
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
Published: 2024-02-26 (Crawled : 12:00) - globenewswire.com
SKYE | $13.1 -6.63% 15K
|
Transportation and Warehousing
|
| O: 6.66%
H: 7.43%
C: 6.72%
sbi-100 glaucoma ocular bioscience hypertension trial
Harvard Eye Associates Now Offering iDose(R) TR as a New Treatment Option to Reduce Eye Pressure in Patients With Ocular Hypertension and Open-Angle Glaucoma
Published: 2024-02-20 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
| Email alert
Add to watchlist
glaucoma ocular offering treatment hypertension eye
Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report 2024-2030, Featuring Glaukos, Johnson & Johnson Vision, AbbVie, Corza Ophthalmology, Lumenis & Ziemer Ophthalmic Systems
Published: 2024-01-23 (Crawled : 11:01) - prnewswire.com
JNJ | News | $147.27 -1.53% 2.3M
|
Health Technology
|
| O: -1.11%
H: 0.0%
C: 0.0%
glaucoma report global market
Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma
Published: 2024-01-11 (Crawled : 00:00) - globenewswire.com
IEX | $222.715 -4.11% 130K
|
Producer Manufacturing
|
| O: 0.55%
H: 0.67%
C: -1.34%
IRIX | $3.03 350
|
Health Technology
|
| O: 0.97%
H: 0.96%
C: -2.89%
532 glaucoma innovation retina disorders laser market
Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors
Published: 2023-12-28 (Crawled : 14:00) - globenewswire.com
SGHT | $5.57 -1.24% 11K
|
|
| O: -2.39%
H: 4.9%
C: -3.32%
glaucoma sciences
Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
Published: 2023-11-28 (Crawled : 12:00) - globenewswire.com
SKYE | $13.1 -6.63% 15K
|
Transportation and Warehousing
|
| O: 3.23%
H: 6.25%
C: -3.13%
sbi-100 glaucoma bioscience study phase 2
Open-Angle Glaucoma Therapeutics Market size to grow by USD 2.36 billion from 2022 to 2027, North America to account for 51% of market growth - Technavio
Published: 2023-11-28 (Crawled : 06:00) - prnewswire.com
NVS | News | $97.515 0.24% 820K
|
Health Technology
|
| O: -0.54%
H: 0.08%
C: -0.22%
BHC | $8.535 0.06% 200K
|
Health Technology
|
| O: -0.73%
H: 1.17%
C: 0.29%
ALC | $79.795 -1.2% 150K
|
Health Technology
|
| O: -0.14%
H: 1.24%
C: 0.53%
ABBV | News | $168.1 -0.85% 670K
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
america glaucoma therapeutics growth market
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
Published: 2023-10-25 (Crawled : 14:00) - biospace.com/
SKYE | $13.1 -6.63% 15K
|
Transportation and Warehousing
|
| O: -0.31%
H: 0.0%
C: -23.0%
sbi-100 glaucoma agonist positive bioscience treatment trial results
Open-Angle Glaucoma Market Size and Share to Accelerate Substantially by 2032, Predicts DelveInsight | Key Companies in the Market - SPARC, AbbVie, Ocuphire, Santen, Glaukos, Ocular Therapeutix, VivaVision Biotech, MediPrint Ophthalmics
Published: 2023-10-12 (Crawled : 21:00) - prnewswire.com
QBIO | $0.0002 100.0% 1.1K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.0%
C: 0.0%
GKOS | $103.29 2.17% 73K
|
Health Technology
|
| O: -0.41%
H: 0.51%
C: -0.21%
OCUL | News | $4.775 -4.5% 800K
|
Health Technology
|
| O: 0.4%
H: 1.18%
C: -1.97%
glaucoma companies ocular market
Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
Published: 2023-10-03 (Crawled : 12:30) - globenewswire.com
SGHT | $5.57 -1.24% 11K
|
|
| O: 0.0%
H: 6.82%
C: 5.93%
omni glaucoma congress sciences system technology
Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial
Published: 2023-09-27 (Crawled : 15:30) - biospace.com/
SKYE | $13.1 -6.63% 15K
|
Transportation and Warehousing
| Email alert
Add to watchlist
glaucoma bioscience trial
Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects
Published: 2023-07-18 (Crawled : 13:00) - biospace.com/
CDXC | $3.47 2.06% 79K
|
Process Industries
|
| O: 0.61%
H: 4.24%
C: 3.03%
glaucoma
Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial
Published: 2023-07-06 (Crawled : 16:00) - biospace.com/
SKYE | $13.1 -6.63% 15K
|
Transportation and Warehousing
|
| O: -9.87%
H: 19.4%
C: 19.4%
glaucoma drug bioscience trial
Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)
Published: 2023-06-21 (Crawled : 12:00) - globenewswire.com
SGHT | $5.57 -1.24% 11K
|
|
| O: 0.24%
H: 0.24%
C: -1.71%
glaucoma
Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System Technology
Published: 2023-05-23 (Crawled : 12:00) - globenewswire.com
SGHT | $5.57 -1.24% 11K
|
|
| O: -0.64%
H: 5.13%
C: -2.16%
omni glaucoma year sciences system technology results show study
Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry
Published: 2023-05-06 (Crawled : 16:20) - globenewswire.com
SGHT | $5.57 -1.24% 11K
|
| Email alert
Add to watchlist
iris glaucoma sciences results
Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Published: 2023-05-01 (Crawled : 20:00) - globenewswire.com
SGHT | $5.57 -1.24% 11K
|
|
| O: -1.23%
H: 4.09%
C: -4.5%
glaucoma meeting eye
Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma
Published: 2023-04-25 (Crawled : 12:00) - prnewswire.com
PTN | $1.73 -1.14% 42K
|
Health Technology
|
| O: 0.0%
H: 1.21%
C: -8.2%
glaucoma conference association treatment research potential
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
LICN | $0.7885 40.8% 11M
|
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.